Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Trade Name Pilot Should Include Third-Party Reviews, Industry Says

Executive Summary

Foreseeing battles over FDA and industry trade name discrepancies in a proposed pilot program, industry representatives are recommending that an independent, third-party review take place

You may also be interested in...



FDA Dangles Trade Name Review Pilot, But Industry Still Looking For The Bait

The success of FDA's pilot program for review of trade names will likely depend on the extent to which companies feel that taking on the burden will produce specific benefits for them

PDUFA Pilots: Risk/Benefit Plan Takes Off As “Continuous” Applications Stop

FDA's proposals for renewal of the Prescription Drug User Fee Act will continue the program's function as an incubator of new regulatory approaches by the agency

Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales

Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.

UsernamePublicRestriction

Register

PS050017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel